BioStem Posts $8.97M Q2 Loss, Flags Going Concern, and Faces $10M Catalyze Payment
BSEM sits 26% above its 52-week low of $3.01 on elevated volume (2.7× avg).
Summary
BioStem Technologies reported a $8.97M Q2 net loss, a going concern warning, and a $10M payment obligation due by September 15, 2026, with cash down to $6.96M.
Key Events · Earnings and Guidance · BSEM
-
Q2 Net Loss of $8.97M
BioStem reported a net loss of $8.97M for Q2 2026, compared to net income of $10.6K in Q2 2025. Six-month net loss was $17.79M vs. net income of $3.92M in H1 2025.
-
Revenue Collapse from CMS Cuts
Physician office revenue fell 90% to $1.10M in Q2 2026 from $10.96M in Q2 2025, driven by CMS reimbursement changes that cut pricing by up to 95% in some cases.
-
Going Concern Warning
Management reiterates substantial doubt about the company's ability to continue as a going concern, citing expected losses and negative cash flows for at least the next twelve months.
-
Cash Down to $6.96M
Cash and cash equivalents fell to $6.96M as of June 30, 2026, from $29.55M at December 31, 2025, a decrease of $22.59M.
Analysis · BSEM · Life Sciences
A dramatic reversal from profitability to an $8.97M net loss marks BioStem's Q2 2026 results, driven by CMS reimbursement cuts that slashed physician office revenue by 90%. Cash has dwindled to $6.96M from $29.55M at year-end, and the company reiterates substantial doubt about its ability to continue as a going concern. The company must pay $10M for the Catalyze product by September 15, 2026, and has already paid $500K in extension fees. This is a critical liquidity crisis for a company with a market cap of only $67.8M.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.5% of the 1055 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSEM was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.8M. The 52-week trading range was $3.01 to $10.71. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.